Skip to content

Current ratio at other companies

Gilead Sciences logo
Gilead SciencesGILD
+0.6×
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
4.2×+0.9×
Arrowhead Research logo
Arrowhead ResearchARWR
6.2×+1.1×
LQD
Liquidia CorporationLQDA
2.2×-0.7×
Alkermes logo
AlkermesALKS
2.3×-1.1×
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
4.1×-5.6×

Other financials

Income statement

See full
Revenue$159.9M+43.3%
Operating income-$789.5M-5,100%
Net income-$790.2M-5,284%
EPS (diluted)-$13.43-4,377%

Balance sheet

See full
Cash & equivalents$261.5M+43.5%
Total debt$13.5M+56.4%
Total equity$242.5M+4.0%
Total assets$890.9M+29.1%

Cash flow

See full
Operating cash flow-$228.8M-11,566%
CapEx$664.0K+1,520%
Free cash flow-$229.4M-11,360%

Valuation

See full
Market cap$6.53B+152%
Enterprise value$6.28B+162%
P/S11.5×+4.6×

Profitability

See full
Operating margin-139.8%-168pp
Net margin-140.2%-169pp
FCF margin-30.3%

Returns & leverage

See full
Return on equity-335.8%-377pp
Debt / equity0.1×0.0×

Where this comes from

Calculated from Mirum Pharmaceuticals, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mirum Pharmaceuticals, Inc.'s current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mirum Pharmaceuticals, Inc.'s current ratio?
Mirum Pharmaceuticals, Inc. (MIRM) reported current ratio of 2.1× in Q1 2026.
How has Mirum Pharmaceuticals, Inc.'s current ratio changed year-over-year?
Mirum Pharmaceuticals, Inc.'s current ratio decreased by 35.2% year-over-year, from 3.2× to 2.1×.
What is the long-term trend for Mirum Pharmaceuticals, Inc.'s current ratio?
Over 5 years (2020 to 2025), Mirum Pharmaceuticals, Inc.'s current ratio has grown at a -26.9% compound annual growth rate (CAGR), from 12.8× to 2.7×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.